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Introduction 
Early-onset lung cancer, often defined as lung cancer in patients less than 50 years of age, has been studied as a rare, but distinct, sub-type of lung cancer. 
Genome-wide association studies (GWAS) have linked several genes with this form of malignancy. Here, we analyze the whole-genome sequences of four 
members of a family (two siblings and the parents), one of which has been diagnosed with lung cancer. Family genome analysis enables us to narrow the 
candidate genes (if any) for this type of cancer, assuming a Mendelian inheritance pattern for early-onset lung cancer. The results of our analysis are discussed 
and conclusions about possible causative mutations for early-onset lung cancer are drawn, demonstrating the value of sequencing the genomes of a complete 
family, especially if an inherited disease is suspected. 
  
*The LUCY study is a multicenter study with 31 participating clinics in Germany, coordinated by the LUCY-Consortium (Head: H.E. Wichmann). 
This work is funded by the University of Luxembourg and the LCSB. This presentation was partly made possible by a Travel Fellowship awarded by ISCB with grant funds 
obtained from the Department of Energy Office of Science, the National Science Foundation Bio-Directorate, and the NIH National Institute of General Medical Sciences. 
 
For more information please contact me at  evangelos.simeonidis@uni.lu or on twitter: @vangos  
 
Results 
The DNA source was blood, which led us to concentrate our analysis 
on Mendelian inheritance models. More than 18 million sequence 
variants were initially identified in the proband through comparison to 
the hg19 reference genome. We reduced this list to fewer than 200 
potentially functional variants (e.g. single nucleotide variations and 
short indels) present in the genomes of the proband and at least one 
parent, by applying a series of filters: 
• Since known variants are potentially of lesser interest, we set aside 
entries that are already catalogued in dbSNP. 
• The criteria for detecting a “potential variant” are extremely lax and 
prone to collecting false positives. Therefore, we retained only entries 
with significant coverage. 
• Because one offspring is affected and the other is not, we removed 
from consideration those potential variants that are observed in both 
the daughter and son. 
• As some variants are expected to have greater impact than others, 
we retained only entries predicted to result in significant alterations in 
protein function or folding. 
 
 
 
 
 
 
 
 
 
are mutated in lung cancer tissue as recorded by The Cancer 
Genome Atlas. 
Conclusions and future work 
We sequenced the genomes of a four member family in which one of 
the offspring had early-onset lung cancer. The analysis did not give 
any matches between the 185 identified genome variants and gene 
candidates from GWAS studies. A limitation of our study was that with 
no access to tumor tissue, we could not look for acquired or somatic 
mutations that might be confined to the tumor itself.  
 
To make the inheritance pattern explicit, we will establish the parental 
origin of the offspring’s genomes through phasing of their 
chromosomes. This will increase the specificity of our analysis and 
allow us to identify variants that might have been missed in the 
above approach. 
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LUCY study family 
We sequenced the genomes of a family quartet in which one of the 
offspring was diagnosed with early-onset lung cancer. The family, 
which participated in the Lung Cancer in the Young (LUCY) GWAS 
study*, has a history of heavy smoking, given in pack-years (P-Y). 
Individual 200, the proband, was diagnosed with adenocarcinoma of 
the lung at the age of 48. Her father, 101, had head and neck cancer 
(sequenced genomes in red). 
 
Whole genome sequencing 
 
 
The genomes of individuals 101, 
102, 200 and 204 were 
sequenced by ABI-Life 
Technologies. The genome of 200 
was also sequenced by Illumina.  
 
Average coverage for the proband 
is 29, whereas for the rest of 
family it is 16. The second 
sequencing of the proband by 
Illumina yielded greater coverage. 
 
There are 18 million sequence  variants (single nucleotide and indel) 
in the proband genome and 14 million in her brother’s genome. 
First plan: study sequence variants in exons only, which yields 84K 
exon variants (reducing the focus to less than 1% of the data). Our 
objective is to narrow the exonic potential variants in the proband 
genome to a smaller set of interesting potential variants.  
We filter for exonic variants that are i) novel; ii) observed with high 
coverage; iii) not observed in the brother’s genome sequence, and; 
iv) have potentially significant protein-coding effects.  
 
 
 
The analysis, after the 
four filtering steps, yields 
185 proband genome 
variants as potential 
mutations of interest. We 
refine the list of candidate 
mutations further by 
comparison to gene 
candidates from GWAS 
studies and genes that  
 
